摘要
目的探讨力扑素联合奈达铂方案治疗晚期非小细胞肺癌(NSCLC)临床效果及患者死亡相关影响因素。方法选取2010年6月至2012年6月间收治的80例NSCLC患者,按照治疗方法分为观察组和对照组,每组40例。观察组给予力扑素联合奈达铂方案治疗,对照组给予力扑素联合顺铂方案治疗。比较两组患者的治疗效果、不良反应、1年生存率以及患者死亡因素。结果观察组患者的总有效率为42.5%(17/40),对照组为37.5%(15/40),差异无统计学意义(P>0.05);观察组患者的呕吐、关节肌疼痛和周围神经炎的发生率分别为17.5%(7/40)、7.5%(3/40)和10.0%(4/40),均显著低于对照组的37.5%(15/40)、25.0%(10/40)和27.5%(11/40,P<0.05);观察组患者1年生存率为65.0%(26/40),对照组为60.0%(24/40),差异无统计学意义(P>0.05);观察组患者的Karnofsky评分为(75±11)分,高于对照组(72±9分,P<0.05);年龄、病情程度、腺癌、积液、肺部感染是患者死亡的重要危险因素(P<0.05)。结论两种治疗方案近期效果无显著差异,但力扑素联合奈达铂方案减轻了患者的不良反应;应积极应对危险因素,提高患者生存时间。
Objective To explore the therapeutic effect and side effect of paclitaxel liposome plus nedaplatin regimen on patients with non-small cell cancer. Methods 80 patients were evenly divided into observation group （40 cases） and control group （40 cases） according to the treatment. The observation group was given the force bashing the prime joint Nedaplatin regimen, the control group a regimen of paelita- xel plus cisplatin. Patients＇ outcomes, adverse reactions, the 1-year survival and death factors of the obser- vation group were compared. Results The total effective rate of observation group was 42. 5% （ 17/40）, the control group 37. 5% （ 15/40）, and the difference was not statistically significant （ P 〉 0. 05 ） ; Inci- dences of vomiting, joint muscle pain and peripheral neuritisthe for observation group were 17.5% （7/40）, 7. 5% （3/40） ,andl0. 0% （4/40） respectively, were lower than those for the control group 37. 5% （ 15/ 40） ,25.0% （10/40） and 27.5% （11/40） respectivly （P 〈 0.05 ）. 1-year survival rate of patients in the observation group was 65.0% （26/40） , the control group 60. 0% （24/40）, the difference was not statisti- cally significant （ P 〉 0. 05 ）. Karnofsky score of the former （ 75 ± 11 ） was significantly higher than the later （72 ±9,P〈0. 05）. Age, severity of disease, adenocarcinoma, effusion, pulmonary infection were major risk factors for death of patients in observation group （ P 〈 0.05 ）. Conclusions Although there was no difference between groups in therapeutic effects, but paelitaxel liposome plus nedaplatin regimen relieved adverse reactions. Active steps against risk factors should be adopted to prolong patients＇ survival.
出处
《中国肿瘤临床与康复》
2013年第9期1001-1004,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
晚期
癌
非小细胞肺
力扑素
奈达铂
Advanced stage
Carcinom
non-small cell lung
Paclitaxel
Nedaplatin
